Skip to content

Efficacy and safety of Lianxiaxiaopi Keli in the treatment of functional dyspepsia (cold-heat complicated syndrome): a randomized, double-blind, placebo parallel, multicenter controlled phase II clinical trial

Efficacy and safety of Lianxiaxiaopi Keli in the treatment of functional dyspepsia (cold-heat complicated syndrome): a randomized, double-blind, placebo parallel, multicenter controlled phase II clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041993
Enrollment
Unknown
Registered
2021-01-12
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional dyspepsia

Interventions

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) The age is 18-65 years old (including the boundary value), and the gender is not limited; (2) They were in accordance with the diagnostic criteria of functional dyspepsia of Western Medicine (Rome IV); (3) According to the syndrome differentiation standard of cold-heat complicated syndrome; (4) In the screening period, the NRS score of at least one symptom of functional dyspepsia (postprandial fullness and discomfort, early satiety, mid upper abdominal pain, mid upper abdominal burning sensation) was >= 4; (5) In the lead-in period, the average NRS score of at least one symptom of functional dyspepsia (postprandial discomfort, early satiety, mid upper abdominal pain, mid upper abdominal burning) was >= 4; (6) No organic abnormality was found in gastroscopy (except chronic non atrophic gastritis); (7) Voluntarily participate in clinical trials, sign informed consent, and understand and follow the research procedures.

Exclusion criteria

Exclusion criteria: (1) Previous diagnosis of dyspepsia caused by organic diseases of digestive system, such as reflux esophagitis, atrophic gastritis, gastrointestinal tumor, hepatobiliary pancreatic disease, inflammatory bowel disease, etc; (2) Patients with diseases affecting the evaluation of digestive symptoms, such as peptic ulcer, intestinal obstruction, erosive gastritis (above grade 2), gastrointestinal bleeding, chronic non atrophic gastritis with polyps; (3) Patients with systemic diseases that seriously affect the digestive tract function, such as hyperthyroidism or hypothyroidism, diabetes, chronic renal insufficiency, connective tissue disease, etc; (4) Patients with severe cardiovascular, cerebrovascular, liver, lung, kidney, blood or systemic diseases affecting their survival; (5) Previous history of abdominal surgery (except appendectomy and cesarean section); (6) The liver function or renal function examination was abnormal and had clinical significance, and the researcher judged that it was not suitable to participate in the trial; (7) The patients who were previously diagnosed with hypertension and had poor blood pressure control (systolic blood pressure >= 140 mmHg, diastolic blood pressure >= 90 mmHg after taking antihypertensive drugs) or with complications; (8) During the trial, we can not stop taking drugs that may affect the effectiveness evaluation of the trial drugs (such as acid suppressor / antacids, non steroidal anti-inflammatory drugs, anticholinergic drugs, glucocorticoids, antidepressants, etc.); (9) Pregnant and lactating women who have fertility planning within 3 months after enrollment to the end of the trial; (10) Suspected or with a history of alcohol or drug abuse; (11) Participated in other clinical trials within one month before screening; (12) Allergic constitution, such as those with a history of allergy to two or more drugs or food, or those known to be allergic to the ingredients of this drug; (13) According to the judgment of the researcher, it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Response rate of dyspepsia symptoms, 8 weeks;Response rate of dyspepsia symptoms, 4/6 weeks;Response rate of postprandial discomfort syndrome, 4/6/8 weeks;Response rate of upper abdominal pain syndrome, 4/6/8 weeks;Dyspepsia symptom score, 2/4/6/8 weeks;Disappearance rate of single dyspepsia symptom, 4/8 weeks;Single symptom of TCM Syndrome, 2/4/6/8 weeks;

Countries

China

Contacts

Public ContactFengpeimin

Affiliated hospital of Chengdu University of Triditional Chinese Medicine

76262251@qq.com+86 18981885791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 15, 2026